About Icons

Icon	Function
💬	A pop-up explanation appears when you mouse-over the text beside this icon. Also, an explanation window appears when you click this icon.
	The links beside this icon are links to external sites.
	Clicking this icon sorts the table by the item with this icon (Numerical or alphabetical order). Each click toggles between ascending and descending order.
	A text longer than 100 characters is fully displayed or collapsed.
	The contents of the displayed table are downloaded as a file named "table.csv".

Drug Description in Trials / DrugBank / KEGG DRUG

Search results

No.

Drug (Description in trials)

DrugBank

KEGG DRUG

KEGG GENES

KEGG PATHWAY

Disease ID

1

ALL patients IN THE study will BE treated with ocrelizumab
(D05218)

-

-

-

-

[1] 13 💬

2

Continued ocrelizumab
(D05218)

-

-

-

-

[1] 13 💬

3

Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
(D05218)

-

-

-

-

[1] 13 💬

4

Natalizumab/natalizumab-sztn, alemtuzumab, ocrelizumab, rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, cladribine, ofatumumab, ublituximab-xiiy, ocrelizumab and hyaluronidase-ocsq
(D05218)

[1] Natalizumab

[1] Natalizumab 💬

[1] ITGA4 💬

[15] Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Cytoskeleton in muscle cells, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬

[1] 13 💬

5

Observation OF ocrelizumab AS treatment IN rrms patients
(D05218)

-

-

-

-

[1] 13 💬

6

Ocrelizumab
(D05218)

[1] Ocrelizumab

[1] Ocrelizumab (D05218) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[4] 11, 13, 46, 49 💬

7

Ocrelizumab / rhumab 2h7
(D05218)

[1] Ocrelizumab

[1] Ocrelizumab (D05218) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 46 💬

8

Ocrelizumab 300 MG
(D05218)

[1] Ocrelizumab

[1] Ocrelizumab (D05218) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

9

Ocrelizumab 300MG
(D05218)

[1] Ocrelizumab

[1] Ocrelizumab (D05218) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

10

Ocrelizumab 300MG/10 ML
(D05218)

[1] Ocrelizumab

[1] Ocrelizumab (D05218) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

11

Ocrelizumab 300MG/10ML
(D05218)

[1] Ocrelizumab

[1] Ocrelizumab (D05218) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

12

Ocrelizumab 500MG
(D05218)

[1] Ocrelizumab

[1] Ocrelizumab (D05218) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 46 💬

13

Ocrelizumab 600 MG
(D05218)

[1] Ocrelizumab

[1] Ocrelizumab (D05218) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

14

Ocrelizumab AT home
(D05218)

[1] Ocrelizumab

[1] Ocrelizumab (D05218) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

15

Ocrelizumab dose 1
(D05218)

[1] Ocrelizumab

[1] Ocrelizumab (D05218) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

16

Ocrelizumab dose 2 and dose 3
(D05218)

[1] Ocrelizumab

[1] Ocrelizumab (D05218) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

17

Ocrelizumab IV
(D05218)

[1] Ocrelizumab

[1] Ocrelizumab (D05218) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

18

Ocrelizumab SC
(D05218)

[1] Ocrelizumab

[1] Ocrelizumab (D05218) 💬

[1] MS4A1 💬

[1] Hematopoietic cell lineage 💬

[1] 13 💬

19

Perfusion OF treatment ocrelizumab
(D05218)

-

-

-

-

[1] 13 💬

20

Short-course ocrelizumab
(D05218)

-

-

-

-

[1] 13 💬